Pharmacokinetically-based prediction of the effects of antibiotic combinations on resistant Staphylococcus aureus mutants: in vitro model studies with linezolid and rifampicin

References

• Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med. 2003;138:135–42.10.7326/0003-4819-138-2-200301210-00015
   PubMed Web of Science ®Google Scholar
• Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis. 2004;39:1010–5.10.1086/cid.2004.39.issue-7
   PubMed Web of Science ®Google Scholar
• Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 2001;358:207–8.10.1016/S0140-6736(01)05410-1
   PubMed Web of Science ®Google Scholar
• Wilson P, Andrews JA, Charlesworth R, Walesby R, Singer M, Farrell DJ, et al. Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother. 2003;51:186–8.10.1093/jac/dkg104
   PubMed Web of Science ®Google Scholar
• Meka VG, Gold HS, Cooke A, Venkataraman L, Eliopoulos GM, Moellering RC, et al. Reversion to susceptibility in a linezolid-resistant clinical isolate of Staphylococcus aureus. J Antimicrob Chemother. 2004;54:818–20.10.1093/jac/dkh423
   PubMed Web of Science ®Google Scholar
• Meka VG, Pillai SK, Sakoulas G, Wennersten C, Venkataraman L, DeGirolami PC, et al. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J Infect Dis. 2004;190:311–7.10.1086/jid.2004.190.issue-2
   PubMed Web of Science ®Google Scholar
• Gales AC, Sader HS, Andrade SS, Lutz L, Machado A, Barth AL. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int J Antimicrob Agents. 2006;27:300–2.10.1016/j.ijantimicag.2005.11.008
   PubMed Web of Science ®Google Scholar
• Hentschke M, Saager B, Horstkotte MA, Scherpe S, Wolters M, Kabisch H, et al. Emergence of linezolid resistance in a methicillin resistant Staphylococcus aureus strain. Infection. 2008;36:85–7.10.1007/s15010-007-7220-7
   PubMed Web of Science ®Google Scholar
• Locke JB, Hilgers M, Shaw KJ. Mutations in ribosomal protein L3 are associated with oxazolidinone resistance in staphylococci of clinical origin. Antimicrob Agents Chemother. 2009;53:5275–8.10.1128/AAC.01032-09
   PubMed Web of Science ®Google Scholar
• Yoshida K, Shoji H, Hanaki H, Yanagisawa C, Ikeda-Dantsuji Y, Fukuchi K, et al. Linezolid-resistant methicillinresistant Staphylococcus aureus isolated after long-term, repeated use of linezolid. J Infect Chemother. 2009;15:417–9.10.1007/s10156-009-0727-3
   PubMed Web of Science ®Google Scholar
• Hill RL, Kearns AM, Nash J, North SE, Pike R, Newson T, et al. Linezolid-resistant ST36 methicillinresistant Staphylococcus aureus associated with prolonged linezolid treatment in two paediatric cystic fibrosis patients. J Antimicrob Chemother. 2010;65:442–5.10.1093/jac/dkp494
   PubMed Web of Science ®Google Scholar
• Ikeda-Dantsuji Y, Hanaki H, Nakae T, Takesue Y, Tomono K, Honda J, et al. Emergence of linezolid-resistant mutants in a susceptible-cell population of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2011;55:2466–8.10.1128/AAC.01548-10
   PubMed Web of Science ®Google Scholar
• Firsov AA, Golikova MV, Strukova EN, Portnoy YA, Romanov AV, Edelstein MV, et al. In vitro resistance studies with bacteria that exhibit low mutation frequencies: prediction of ‘antimutant’ linezolid concentrations using a mixed inoculum containing both susceptible and resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2015;59:1014–9.10.1128/AAC.04214-14
   PubMed Web of Science ®Google Scholar
• Alieva KN, Strukova EN, Portnoy YA, Golikova MV, Zinner SH, Firsov AA. Testing the mutant selection window hypothesis in Staphylococcus aureus resistance studies with linezolid using a mixture of antibiotic-susceptible cells and resistant mutants in an in vitro dynamic model. Abstr 26th Europ Congr Clin Microbiol Infect Dis. 2016. Abstr. P-1195. https://www.escmid.org/escmid_publications/escmid_elibrary/?q=Firsov&id=2173&L=0&x=0&y=0.
   Google Scholar
• CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard. CLSI document M-07-08. 8th ed. Wayne, PA: CLSI; 2009.
   Google Scholar
• Meagher AK, Forrest A, Rayner CR, Birmingham MC, Schentag JJ. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother. 2003;47:548–53.10.1128/AAC.47.2.548-553.2003
   PubMed Web of Science ®Google Scholar
• Peloquin CA, Namdar R, Singleton MD, Nix DE. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest. 1999;115:12–18.10.1378/chest.115.1.12
   PubMed Web of Science ®Google Scholar
• Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet. 2003;42:1129–40.10.2165/00003088-200342130-00004
   PubMed Web of Science ®Google Scholar
• Acocella G. Pharmacokinetics and metabolism of rifampin in humans. Rev Infect Dis. 1983;5(Suppl 3):S428–32.10.1093/clinids/5.Supplement_3.S428
   PubMedGoogle Scholar
• Firsov AA, Shevchenko AA, Vostrov SN, Zinner SH. Inter- and intra-quinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. Antimicrob Agents Chemother. 1998;42:659–65.
   PubMed Web of Science ®Google Scholar
• Blaser J, Stone BB, Zinner SH. Two compartment kinetic model with multiple artificial capillary units. J Antimicrob Chemother. 1985;15(Suppl A):131–7.10.1093/jac/15.suppl_A.131
   PubMed Web of Science ®Google Scholar
• Firsov AA, Smirnova MV, Strukova EN, Vostrov SN, Portnoy YA, Zinner SH. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion. Int J Antimicrob Agents. 2008;32:488–93.10.1016/j.ijantimicag.2008.06.031
   PubMed Web of Science ®Google Scholar
• Blondeau JM, Zhao X, Hansen G, Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2001;45:433–8.10.1128/AAC.45.2.433-438.2001
   PubMed Web of Science ®Google Scholar
• Campion JJ, McNamara PJ, Evans ME. Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments. Antimicrob Agents Chemother. 2004;48:4733–44.10.1128/AAC.48.12.4733-4744.2004
   PubMed Web of Science ®Google Scholar
• Liang B, Bai N, Cai Y, Wang R, Drlica K, Zhao X. Mutant prevention concentration-based pharmacokinetic/pharmacodynamic indices as dosing targets for suppressing the enrichment of levofloxacin-resistant subpopulations of Staphylococcus aureus. Antimicrob Agents Chemother. 2011;55:2409–12.10.1128/AAC.00975-10
   PubMed Web of Science ®Google Scholar
• Firsov AA, Strukova EN, Portnoy YA, Shlykova DS, Zinner SH. Bacterial antibiotic resistance studies using in vitro dynamic models: Population analysis vs. susceptibility testing as endpoints of mutant enrichment. Int J Antimicrob Agents. 2015;46:313–8.10.1016/j.ijantimicag.2015.06.007
   PubMed Web of Science ®Google Scholar
• Strukova EN, Portnoy YA, Zinner SH, Firsov AA. Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentration. J Antimicrob Chemother. 2016;71:678–84.10.1093/jac/dkv387
   PubMed Web of Science ®Google Scholar
• Strukova EN, Portnoy YA, Romanov AV, Edelstein MV, Zinner SH, Firsov AA. Searching for the optimal predictor of ciprofloxacin resistance in Klebsiella pneumoniae by using in vitro dynamic models. Antimicrob Agents Chemother. 2016;60:1208–15.10.1128/AAC.02334-15
   Web of Science ®Google Scholar
• Zhanel GG, Mayer M, Laing N, Adam HJ. Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006;50:2228–30.10.1128/AAC.01620-05
   PubMed Web of Science ®Google Scholar
• Cai Y, Yang J, Kan Q, Nie X, Wang R, Liang B, Bai N. Mutant prevention concentration of colistin alone and in combination with levofloxacin or tobramycin against multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2012;40:477–8.10.1016/j.ijantimicag.2012.06.018
   PubMed Web of Science ®Google Scholar
• Liu LG, Zhu YL, Hu LF, Cheng J, Ye Y, Li JB. Comparative study of the mutant prevention concentrations of vancomycin alone and in combination with levofloxacin, rifampicin and fosfomycin against methicillin-resistant Staphylococcus epidermidis. J Antibiot. 2013;66:709–12.10.1038/ja.2013.87
   PubMed Web of Science ®Google Scholar
• Wei W, Yang H, Hu L, Ye Y, Li J. Activity of levofloxacin in combination with colistin against Acinetobacter baumannii: in vitro and in a Galleria mellonella model. J Microbiol Immunol Infect. 2015 Nov 26. pii: S1684-1182(15)00907-X. doi: 10.1016/j.jmii.2015.10.010. [Epub ahead of print].
   Google Scholar
• Wu J, Jiang TT, Su JR, Li L. Antimicrobial activity of linezolid combined with minocycline against vancomycin-resistant Enterococci. Chin Med J. 2013;126:2670–5.
   PubMed Web of Science ®Google Scholar
• Egle H, Trittler R, Kummerer K, Lemmen SW. Linezolid and rifampin: Drug interaction contrary to expectations? Clin Pharmacol Ther. 2005;77:451–3.10.1016/j.clpt.2005.01.020
   PubMed Web of Science ®Google Scholar
• Gandelman K, Zhu T, Fahmi OA, Glue P, Lian K, Obach RS, et al. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J Clin Pharmacol. 2011;51:229–36.10.1177/0091270010366445
   PubMed Web of Science ®Google Scholar
• Gebhart BC, Barker BC, Markewitz BA. Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin. Pharmacotherapy. 2007;27:476–9.10.1592/phco.27.3.476
   PubMed Web of Science ®Google Scholar
• Gervasoni C, Simonetti FR, Resnati C, Charbe N, Clementi E, Cattaneo D. Prolonged inductive effect of rifampicin on linezolid exposure. Eur J Clin Pharmacol. 2015;71:643–4.10.1007/s00228-015-1833-z
   PubMed Web of Science ®Google Scholar
• Hoyo I, Martínez-Pastor J, Garcia-Ramiro S, Climent C, Brunet M, Cuesta M, et al. Decreased serum linezolid concentrations in two patients receiving linezolid and rifampicin due to bone infections. Scand J Infect Dis. 2012;44:548–50.10.3109/00365548.2012.663931
   PubMed Web of Science ®Google Scholar
• Blassmann U, Roehr AC, Frey OR, Koeberer A, Briegel J, Huge V, et al. Decreased linezolid serum concentrations in three critically ill patients: clinical case studies of a potential drug interaction between linezolid and rifampicin. Pharmacology. 2016;98:51–5.10.1159/000445194
   PubMed Web of Science ®Google Scholar